The long-term objective of the applicant's research is to develop clinically applicable methods to attain durable function of porcine lung in man. In order to achieve this goal, specific mechanisms mediating hyperacute lung rejection of pig lungs perfused with human blood must be elucidated and controlled. Complement activation is an important mechanism mediating hyperacute rejection in porcine-to-primate xenotransplantation. We hypothesize that expression of human decay-accelerating factor (hDAF) in pig lung will inhibit complement activation in the lung and subsequently inhibit hyperacute rejection of the lung by human blood. We will evaluate the efficacy of transgenic hDAF expression on porcine endothelium in deterring the vasoconstrictive and cytotoxic events identified during hyperacute pulmonary rejection. We will also apply pharmacologic and biochemical studies to elucidate relative contributions of complement-dependent and - independent mechanisms of injury in our model of hDAF transgenic pulmonary xenotransplantation. With these studies we propose to determine whether complement inhibition, likely in conjunction with modulation of complement- independent mechanisms, will prove important in preventing hyperacute rejection of pulmonary xenografts.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32HL009591-02
Application #
2445078
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1997-01-28
Project End
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Surgery
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Chang, A C; Shyr, Y; Groves, J et al. (1999) The utility of exercise testing after cardiac transplantation in older patients. J Surg Res 81:48-54
Chang, A C; Blum, M G; Blair, K S et al. (1999) Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival. Transplant Proc 31:95
Pierson 3rd, R N; Chang, A C; Blum, M G et al. (1999) Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. Transplantation 68:1800-5